Eric Siemers, MD, has over 25 years of experience in clinical trials of neurodegenerative disease. His research research focus is on the use of biomarkers in investigational drug research, the development of trial designs that fully characterize the effects of investigational drugs on chronic diseases, and more specifically, the development of strategies for treating individuals before the onset of symptoms of neurodegenerative diseases.

Dr. Siemers most recently served as a distinguished medical fellow for Eli Lilly and Company’s Alzheimer’s Disease Global Development Team, where he was responsible for the design and implementation of five large Phase III clinical studies, in addition to playing a major collaborative role in 2 public-private partnership studies.

Prior to his appointments at Lilly, Dr. Siemers founded and headed the Indiana University Movement Disorder Clinic; his research there included investigations of Parkinson’s and Huntington’s diseases, and he established one of the first centers for surgical Parkinson's treatments in the US.

Dr. Siemers served on the Board of Directors of the American Society of Experimental Neurotherapeutics, as founding member and Chair of the Alzheimer’s Association Research Roundtable, and Steering Committee member for the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Dr. Siemers earned his medical degree with highest distinction from the Indiana University School of Medicine, where he completed an internship in the Department of Internal Medicine and residency in the Department of Neurology.